Amgen executives detailed their alleged Aranesp "overfill" kickback scheme in a set of PowerPoint slides and Excel spreadsheets, according to a lawsuit filed by the New York State Attorney General.

Biopharmaceutical manufacturer Amgen is the latest company to receive an Untitled Letter from the US Food and Drug Administration's (FDA) Office of Prescription Drug Promotion (OPDP), the latest in a ...

Getting your Trinity Audio player ready... PHILADELPHIA- In the latest blow to Amgen Inc., at least one company that administers Medicare plans has decided to stop paying for the use of the drug ...

Aranesp "145 Study" Shows No Difference in Survival in Patients with Small-Cell Lung Cancer THOUSAND OAKS, Calif. -- Apr 19, 2007 - Amgen today announced the results of the "145 study", a randomized, ...

WASHINGTON, Feb. 20 (UPI) -- Amgen shares slipped Friday after it was revealed a trial involving Aranesp was halted early due to an increased risk of recurrence of tumors in cancer patients, but some ...

Amgen Inc. filed for government approval to market Aranesp, its next-generation anemia drug, for treatment of chemotherapy-induced anemia, a potential $4.7-billion market. The application is expected ...

More bad news for Amgen and its beleaguered anemia drug franchise: A giant trial finds the company's Aranesp drug nearly doubles the risk of strokes in kidney disease patients. Aranesp sales have ...

DUBLIN--(BUSINESS WIRE)--The "Darbepoetin Alfa (Aranesp) Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global darbepoetin alfa (Aranesp) market is expected ...

Amgen Inc.’s anemia treatment Aranesp is safe for use in kidney patients whose disease doesn’t require dialysis, a U.S. panel found. Outside advisors to the Food and Drug Administration said the ...

In a new setback for Amgen , a U.S. Food and Drug Administration committee has voted to restrict the usage of the company's blockbuster anemia drug, sending the biotech firm's stock tumbling on Friday ...

Amgen’s anaemia drug Aranesp has been dealt a further blow after it was confirmed that full results from a Phase III clinical study showed a higher rate of death in cancer patients receiving the drug.